Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lantern Pharma Inc LTRN

Healthcare Biotechnology
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LTRN)

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC(TM) Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Business Wire 4 days ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Business Wire November 7, 2024

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Business Wire November 5, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Business Wire October 31, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Business Wire October 23, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

Business Wire October 21, 2024

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Business Wire October 15, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Business Wire September 23, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Business Wire August 8, 2024
View More News ››

Opinion & Analysis (NDAQ:LTRN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LTRN)

&#xA0;Lantern Pharma Highlights Promising Preclinical Result

Breaking News: $LTRN &#xA0;Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint...
whytestocks - August 7, 2024

BUY BUY BUY BUY BUY

To hit 8$ today
Nibinator - August 7, 2024
View more Bullboard ››

Pinnacle Silver & Gold Corp

Pinnacle Silver & Gold Corp

Pinnacle is currently focused on district-scale exploration for precious metals in the prolific Red Lake District of ...
View More »